N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=118 Next Generation Cataract and Vitreoretinal Surgery Study
Vitreoretinal Disease With or Without Cataracts
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in…
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
N/A N=20 Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
Pseudophakia
Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR
Phase 3 N=702 Treatment for CI-DME in Eyes With Very Good VA Study
Diabetic Macular Edema
Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
N/A N=11 Triamcinolone vs. Laser for Diabetic Macular Edema
DIABETIC MACULAR EDEMA
Primary: Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.
Phase 4 N=112 Isotretinoin for Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy
Primary: Rate of Retinal Attachment — 50; 42 Participants
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 2 N=12 Aflibercept Injection for Proliferative Diabetic Retinopathy
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Phase 1 N=4 Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Rubeosis Iridis · Proliferative Diabetic Retinopathy
Primary: Adverse Event (AE) — 0 participants
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Early Phase 1 N=9 Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Reticular Pseudodrusen (RPD) · Age-Related Macular Degeneration
Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…
Phase 1 N=40 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 1 N=14 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
Phase 3 N=399 Anti-VEGF Treatment for Prevention of PDR/DME
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes
Phase 2 N=130 Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
Diabetic Macular Edema
Primary: BCVA — 0.8; -0.3; -1.8 Letters
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
N/A N=12 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I
Uveomeningoencephalitic Syndrome · Inflammation · Choroid Disease
Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001
Phase 2 N=91 Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Inflammation
Primary: Anterior Chamber Cell: Categorical Cure — 18; 16; 6 Participants
N/A N=448 Safety and Suitability of ICL for Correction of Refractive Errors Without the Use of Dispersive OVDs
Refractive Errors · Myopia · Myopic Astigmatism
Primary: Unaided Visual Acuity After the Procedure — 0.264; 0.227 LogMar vision
Phase 2 N=109 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
Diabetic Retinopathy
Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants
Phase 3 N=188 Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Age-related Macular Degeneration · Depression
Primary: Depression — 11; 18; 5; 11 participants — p=.067